As of my last update in October 2023, DK419, with the CAS number 2102672-22-8, is a chemical compound that has garnered interest in the field of medicinal chemistry, particularly for its potential therapeutic applications. While specific characteristics such as molecular weight, structure, and solubility may vary, compounds like DK419 are typically evaluated for their biological activity, pharmacokinetics, and safety profiles. Such substances are often studied for their interactions with biological targets, which can include enzymes or receptors, and may exhibit properties such as anti-inflammatory or anti-cancer effects. The synthesis and characterization of DK419 would involve standard organic chemistry techniques, and its efficacy would be assessed through various in vitro and in vivo studies. For precise details regarding its physical and chemical properties, as well as its mechanism of action, consulting scientific literature or databases dedicated to chemical substances would be essential.

DK419 is a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth. DK419 inhibited Wnt/β-catenin signaling, altered cellular oxygen consumption rate and induced production of pAMPK. DK419 inhibited the growth of CRC tumor cells in vitro, had good plasma exposure when dosed orally, and inhibited the growth of patient derived CRC240 tumor explants in mice dosed orally.

DK419

2102672-22-8: As of my last update in October 2023, DK419, with the CAS number 2102672-22-8, is a chemical compound that has garnered interest in the field of medicinal chemistry, particularly for its potential therapeutic applications. While specific characteristics such as molecular weight, structure, and solubility may vary, compounds like DK419 are typically evaluated for their biological activity, pharmacokinetics, and safety profiles. Such substances are often studied for their interactions with biological targets, which can include enzymes or receptors, and may exhibit properties such as anti-inflammatory or anti-cancer effects. The synthesis and characterization of DK419 would involve standard organic chemistry techniques, and its efficacy would be assessed through various in vitro and in vivo studies. For precise details regarding its physical and chemical properties, as well as its mechanism of action, consulting scientific literature or databases dedicated to chemical substances would be essential.

DK419 is an orally active inhibitor of Wnt/β-catenin signaling, with an IC50 of 0.19 μM.

CAS 2102672-22-8

DK419

DK419

Ref: 54-BUP14369

DK419

Ref: TM-T15137